Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Aveni Foundation
Servier
Var2 Pharmaceuticals
IGM Biosciences, Inc.
Taproot Health
TopAlliance Biosciences
Celgene
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Assaf-Harofeh Medical Center
Celldex Therapeutics
Rutgers, The State University of New Jersey
Valerio Therapeutics
Valerio Therapeutics
University of South Florida
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center